Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Alopecia areata in children, adolescents, and adults
New Guideline Classifies the Evidence Base for Topical and Systemic Therapies
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases